If an FDA appeal decision goes in Amarin's favor, the stock is moving much higher.
Aegerion offers brighter-than-expected sales outlook; Sarepta up on FDA response to petition.
Across just about every biomarker for efficacy Galectin thought to measure, GR-MD-02 showed no difference from placebo in a phase I study.
Like Galena BioPharma and The DreamTeam Group, Galectin is also paying for a promotional campaign designed to entice retail investors into buying its stock.
Express Scripts and CVS Caremark are the largest and second-largest pharmacy benefits managers in the U.S. Both have been aggressive with efforts to rein in ever-escalating drug prices.
AcelRx believes it can gather all the requested information and re-submit Zalviso to the FDA before the end of the year.
MannKind must report second-quarter financials before the end of the second week in August, which sets a quasi-deadline for Afrezza partner plans.
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Sarepta terminates Chief Scientific Officer Art Krieg. Here's what I've learned about why he was fired.
In its first two quarters on the market, Sovaldi, a pill used to treat hepatitis C, has delivered $5.8 billion in revenue to Gilead. Remarkable.